{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:08:50Z","timestamp":1789556930295,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:00:00Z","timestamp":1550102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AZ IRESSA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00280-019-03788-4","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T10:09:48Z","timestamp":1550138988000},"page":"849-858","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer"],"prefix":"10.1007","volume":"83","author":[{"given":"Toshio","family":"Kawata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Higashimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohji","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Tomkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Nyberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tanigawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,14]]},"reference":[{"key":"3788_CR1","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1200\/JCO.2005.08.409","volume":"23","author":"G Giaccone","year":"2005","unstructured":"Giaccone G (2005) Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 23:3235\u20133242. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.08.409","journal-title":"J Clin Oncol"},{"key":"3788_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.lungcan.2010.12.006","volume":"73","author":"S Liu","year":"2011","unstructured":"Liu S, Wang D, Chen B, Wang Y, Zhao W, Wu J (2011) The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status. Lung Cancer 73:203\u2013210. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2010.12.006","journal-title":"Lung Cancer"},{"key":"3788_CR3","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","volume":"177","author":"S Kudoh","year":"2008","unstructured":"Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y et al (2008) Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case\u2013control study. Am J Respir Crit Care Med 177:1348\u20131357. \n                    https:\/\/doi.org\/10.1164\/rccm.200710-1501OC","journal-title":"Am J Respir Crit Care Med"},{"key":"3788_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","volume":"165","author":"American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias","year":"2002","unstructured":"American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias (2002) This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165:277\u2013304. \n                    https:\/\/doi.org\/10.1164\/ajrccm.165.2.ats01","journal-title":"Am J Respir Crit Care Med"},{"key":"3788_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0140-6736(03)12190-3","volume":"361","author":"A Inoue","year":"2003","unstructured":"Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y et al (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361:137\u2013139. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(03)12190-3","journal-title":"Lancet"},{"issue":"Suppl 2","key":"3788_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1038\/sj.bjc.6602061","volume":"91","author":"G Raghu","year":"2004","unstructured":"Raghu G, Nyberg F, Morgan G (2004) The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer 91(Suppl 2):S3\u2013S10. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6602061","journal-title":"Br J Cancer"},{"key":"3788_CR7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/pds.1071","volume":"14","author":"L Koo","year":"2005","unstructured":"Koo L, Clark J, Quesenberry CP, Higenbottam T, Nyberg F, Wolf M et al (2005) National differences in reporting \u2018pneumonia\u2019 and \u2018pneumonia interstitial\u2019: an analysis of the WHO drug monitoring database on 15 drugs in nine countries for seven pulmonary conditions. Pharmacoepidemiol Drug Saf 14:775\u2013787. \n                    https:\/\/doi.org\/10.1002\/pds.1071","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3788_CR8","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1200\/JCO.2006.06.1044","volume":"24","author":"S Kudoh","year":"2006","unstructured":"Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K et al (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24:3657\u20133663. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.06.1044","journal-title":"J Clin Oncol"},{"key":"3788_CR9","first-page":"405","volume":"50","author":"A Azuma","year":"2007","unstructured":"Azuma A, Kudoh S (2007) High prevalence of drug-induced pneumonia in Japan. Japan Med Assoc J 50:405\u2013411","journal-title":"Japan Med Assoc J"},{"key":"3788_CR10","doi-asserted-by":"publisher","first-page":"e22062","DOI":"10.1371\/journal.pone.0022062","volume":"6","author":"F Nyberg","year":"2011","unstructured":"Nyberg F, Ogiwara A, Harbron CG, Kawakami T, Nagasaka K, Takami S et al (2011) Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patients. PLoS One 6:e22062. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0022062","journal-title":"PLoS One"},{"key":"3788_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.lungcan.2016.01.005","volume":"93","author":"T Hirose","year":"2016","unstructured":"Hirose T, Fujita K, Kusumoto S, Oki Y, Murata Y, Sugiyama T et al (2016) Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung Cancer 93:69\u201376. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2016.01.005","journal-title":"Lung Cancer"},{"key":"3788_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00280-016-3097-4","volume":"78","author":"K Mizoguchi","year":"2016","unstructured":"Mizoguchi K, Nakamura Y, Sano K, Sato S, Ikegami Y, Motoshima K et al (2016) Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations. Cancer Chemother Pharmacol 78:377\u2013382. \n                    https:\/\/doi.org\/10.1007\/s00280-016-3097-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"3788_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cllc.2014.12.004","volume":"16","author":"H Kobayashi","year":"2015","unstructured":"Kobayashi H, Sato K, Niioka T, Miura H, Ito H, Miura M (2015) Relationship among gefitinib exposure, polymorphisms of its metabolizing enzymes and transporters, and side effects in Japanese patients with non-small-cell lung cancer. Clin Lung Cancer 16:274\u2013281. \n                    https:\/\/doi.org\/10.1016\/j.cllc.2014.12.004","journal-title":"Clin Lung Cancer"},{"key":"3788_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0021-9681(72)90027-6","volume":"25","author":"A Keys","year":"1972","unstructured":"Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL (1972) Indices of relative weight and obesity. J Chronic Dis 25:329\u2013343","journal-title":"J Chronic Dis"},{"key":"3788_CR15","volume-title":"Physique sociale","author":"LAJ Quetelet","year":"1869","unstructured":"Quetelet LAJ (1869) Physique sociale, vol\u00a02. C. Muquardt, Brussels"},{"key":"3788_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341. \n                    https:\/\/doi.org\/10.1159\/000180580","journal-title":"Nephron"},{"key":"3788_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0731-7085(02)00014-6","volume":"29","author":"HK Jones","year":"2002","unstructured":"Jones HK, Stafford LE, Swaisland HC, Payne R (2002) A sensitive assay for ZD1839 (\u2018Iressa\u2019) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials. J Pharm Biomed Anal 29:221\u2013228. \n                    https:\/\/doi.org\/10.1016\/S0731-7085(02)00014-6","journal-title":"J Pharm Biomed Anal"},{"key":"3788_CR18","volume-title":"NONMEM users guide","author":"SL Beal","year":"1998","unstructured":"Beal SL, Sheiner LB (1998) NONMEM users guide. University of California, California"},{"key":"3788_CR19","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/00498250400009171","volume":"34","author":"D McKillop","year":"2004","unstructured":"McKillop D, Hutchison M, Partridge EA, Bushby N, Cooper CMF, Clarkson-Jones JA et al (2004) Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica 34:917\u2013934. \n                    https:\/\/doi.org\/10.1080\/00498250400009171","journal-title":"Xenobiotica"},{"key":"3788_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/00498250400026464","volume":"35","author":"D McKillop","year":"2005","unstructured":"McKillop D, McCormick AD, Millar A, Miles GS, Phillips PJ, Hutchison M (2005) Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica 35:39\u201350. \n                    https:\/\/doi.org\/10.1080\/00498250400026464","journal-title":"Xenobiotica"},{"key":"3788_CR21","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2165\/00003088-200544100-00005","volume":"44","author":"HC Swaisland","year":"2005","unstructured":"Swaisland HC, Ranson M, Smith RP, Leadbetter J, Laight A, McKillop D et al (2005) Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 44:1067\u20131081. \n                    https:\/\/doi.org\/10.2165\/00003088-200544100-00005","journal-title":"Clin Pharmacokinet"},{"key":"3788_CR22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/cpdd.337","volume":"6","author":"W Tang","year":"2017","unstructured":"Tang W, Tomkinson H, Masson E (2017) Effect of sustained elevated gastric pH levels on gefitinib exposure. Clin Pharmacol Drug Dev 6:517\u2013523. \n                    https:\/\/doi.org\/10.1002\/cpdd.337","journal-title":"Clin Pharmacol Drug Dev"},{"key":"3788_CR23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/0973-1482.95201","volume":"8","author":"Y Tsubata","year":"2012","unstructured":"Tsubata Y, Hamada A, Sutani A, Isobe T (2012) Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient. J Cancer Res Ther 8:154\u2013156. \n                    https:\/\/doi.org\/10.4103\/0973-1482.95201","journal-title":"J Cancer Res Ther"},{"key":"3788_CR24","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40262-013-0058-5","volume":"52","author":"M Fukudo","year":"2013","unstructured":"Fukudo M, Ikemi Y, Togashi Y, Masago K, Kim YH, Mio T et al (2013) Population pharmacokinetics\/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clin Pharmacokinet 52:593\u2013609. \n                    https:\/\/doi.org\/10.1007\/s40262-013-0058-5","journal-title":"Clin Pharmacokinet"},{"key":"3788_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/jcpt.12232","volume":"40","author":"Y Emoto-Yamamoto","year":"2015","unstructured":"Emoto-Yamamoto Y, Iida S, Kawanishi T, Fukuoka M (2015) Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer. J Clin Pharm Ther 40:232\u2013239. \n                    https:\/\/doi.org\/10.1111\/jcpt.12232","journal-title":"J Clin Pharm Ther"},{"key":"3788_CR26","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1164\/ajrccm.161.6.9812022","volume":"161","author":"MM Heuvel Van Den","year":"2000","unstructured":"Van Den Heuvel MM, Poland DC, De Graaff CS, Hoefsmit EC, Postmus PE, Beelen RH et al (2000) The degree of branching of the glycans of alpha(1)-acid glycoprotein in asthma. A correlation with lung function and inflammatory parameters. Am J Respir Crit Care Med 161:1972\u20131978. \n                    https:\/\/doi.org\/10.1164\/ajrccm.161.6.9812022","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03788-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03788-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03788-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:25:49Z","timestamp":1581639949000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03788-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,14]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["3788"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03788-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,14]]},"assertion":[{"value":"4 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Toshio Kawata, Mitsuo Higashimori, Yohji Itoh, Helen Tomkinson, Martin G Johnson, Weifeng Tang, Fredrik Nyberg, and Haiyi Jiang are employees and stockholders in AstraZeneca. Professor Yusuke Tanigawara declares no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}